Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Immunogencity of H7N9 Influenza Antigen With 2 Adjuvant Formulations in Healthy Adults in Brazil

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03330899
Recruitment Status : Completed
First Posted : November 6, 2017
Last Update Posted : September 30, 2020
Sponsor:
Information provided by (Responsible Party):
Butantan Institute

Brief Summary:
The overall aim of this study is to evaluate the safety, immunogenicity and dose sparing effects of H7N9 influenza antigen formulated with 2 different adjuvants .

Condition or disease Intervention/treatment Phase
Influenza H7N9 Influenza Biological: H7N9 antigen + adjuvant IB160 Biological: H7N9 antigen + adjuvant SE Biological: H7N9 antigen without adjuvant Biological: Placebo (PBS) Phase 1

Detailed Description:
Following the emergence of avian influenza A/H7N9 influenza virus in humans in China in March 2013, the WHO Essential Regulatory Laboratories prepared candidate vaccine viruses and reagents for further development and several manufacturers have developed various inactivated influenza vaccines with and without adjuvant against A/H7N9 and tested these candidates in trials in healthy adults. The overall aim of this study is to evaluate the safety, immunogenicity and dose sparing effects of H7N9 influenza antigen produced by Butantan Institute in combination with 2 different adjuvants.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 432 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Phase I Randomized, Double-blind, Placebo-controlled, Dose Finding Clinical Trial to Evaluate the Safety and Immunogencity of H7N9 Influenza Antigen Adjuvanted With 2 Different Adjuvant Formulations in Healthy Adult Volunteers in Brazil
Actual Study Start Date : September 24, 2018
Actual Primary Completion Date : January 30, 2020
Actual Study Completion Date : August 25, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: 15 mcg H7N9 + adjuvant IB160

Participants in this arm will receive one dose of the combination (15 mcg H7N9 antigen + adjuvant IB160) at Day 0 and another dose at Day 28.

Each dose after combination = 0,5 ml 15 mcg of the monovalent H7N9 antigen per dose

Biological: H7N9 antigen + adjuvant IB160
H7N9 monovalent (fragmented and inactivated)

Active Comparator: 7.5 mcg H7N9 + adjuvant IB160

Participants in this arm will receive one dose of the combination (7.5 mcg H7N9 antigen + adjuvant IB160) at Day 0 and another dose at Day 28.

Each dose after combination = 0,5 ml 7.5 mcg of the monovalent H7N9 antigen per dose

Biological: H7N9 antigen + adjuvant IB160
H7N9 monovalent (fragmented and inactivated)

Active Comparator: 3.75 mcg H7N9 + adjuvant IB160

Participants in this arm will receive one dose of the combination (3.75 mcg H7N9 antigen + adjuvant IB160) at Day 0 and another dose at Day 28.

Each dose after combination = 0,5 ml 3.75 mcg of the monovalent H7N9 antigen per dose

Biological: H7N9 antigen + adjuvant IB160
H7N9 monovalent (fragmented and inactivated)

Active Comparator: 15 mcg H7N9 + adjuvant SE

Participants in this arm will receive one dose of the combination (15 mcg H7N9 antigen + adjuvant SE) at Day 0 and another dose at Day 28.

Each dose after combination = 0,5 ml 15 mcg of the monovalent H7N9 antigen per dose

Biological: H7N9 antigen + adjuvant SE
H7N9 monovalent (fragmented and inactivated)

Active Comparator: 7.5 mcg H7N9 + adjuvant SE

Participants in this arm will receive one dose of the combination (7.5 mcg H7N9 antigen + adjuvant SE) at Day 0 and another dose at Day 28.

Each dose after combination = 0,5 ml 7.5 mcg of the monovalent H7N9 antigen per dose

Biological: H7N9 antigen + adjuvant SE
H7N9 monovalent (fragmented and inactivated)

Active Comparator: 3.75 mcg H7N9 + adjuvant SE

Participants in this arm will receive one dose of the combination (3.75 mcg H7N9 antigen + adjuvant SE) at Day 0 and another dose at Day 28.

Each dose after combination = 0,5 ml 3.75 mcg of the monovalent H7N9 antigen per dose

Biological: H7N9 antigen + adjuvant SE
H7N9 monovalent (fragmented and inactivated)

Active Comparator: 15 mcg H7N9 without adjuvant

Participants in this arm will receive one dose of the 15 mcg H7N9 antigen without adjuvant at Day 0 and another dose at Day 28.

Each dose = 0,5 ml

Biological: H7N9 antigen without adjuvant
H7N9 monovalent (fragmented and inactivated)

Placebo Comparator: Placebo (PBS)

Participants in this arm will receive one dose of Placebo (PBS) at Day 0 and another dose at Day 28.

Each dose = 0,5 ml

Biological: Placebo (PBS)
Placebo (Phosphate Buffered Saline -PBS)




Primary Outcome Measures :
  1. Number of participants with solicited local Adverse Events over the 7-day period post each study injection. [ Time Frame: 7-day period post each study injection (Days 0-6) ]

    Solicited local Adverse Events (AE) include erythema, swelling/induration, pain/tenderness, ecchymosis, pruritis.

    The participant will be given a Participant Diary, a digital thermometer and ruler in which the participant will be asked to record any local and/or systemic reactions.

    The participant will have been instructed that if he/she experiences an AE requiring medical care, the participant should inform the study staff as soon as possible and seek medical care as appropriate.

    A visit will be schedule to occur 7 days after each study injection. Study staff will review the Participant Diary and interim history with the participant and inquire about new medical events, which will be recorded in the appropriate Clinical Research Forms.


  2. Number of participants with solicited systemic Adverse Effects over the 7-day period post each study injection. [ Time Frame: 7-day period post each study injection (Days 0-6) ]

    Solicited systemic Adverse Events (AE) include fever, fatigue/malaise, myalgia, arthralgia, chills, nausea/vomiting, and headache.

    The participant will be given a Participant Diary, a digital thermometer and ruler in which the participant will be asked to record any local and/or systemic reactions.

    The participant will have been instructed that if he/she experiences an AE requiring medical care, the participant should inform the study staff as soon as possible and seek medical care as appropriate.

    A visit will be schedule to occur 7 days after each study injection. Study staff will review the Participant Diary and interim history with the participant and inquire about new medical events, which will be recorded in the appropriate Clinical Research Forms.


  3. Number of participants with unsolicited local and/or systemic Adverse Events over the 7-day period post each study injection. [ Time Frame: 7-day period post each study injection (Days 0-6) ]

    Unsolicited local and/or systemic Adverse Events include any AE not include in the description of solicited AE, as described in Outcome 1 and 2.

    The participant will be given a Participant Diary, a digital thermometer and ruler in which the participant will be asked to record any local and/or systemic reactions.

    The participant will have been instructed that if he/she experiences an AE requiring medical care, the participant should inform the study staff as soon as possible and seek medical care as appropriate.

    A visit will be schedule to occur 7 days after each study injection. Study staff will review the Participant Diary and interim history with the participant and inquire about new medical events, which will be recorded in the appropriate Clinical Research Forms.



Secondary Outcome Measures :
  1. Number of participants with unsolicited local and/or systemic Adverse Events over the 28-day period post each study injection. [ Time Frame: 28-day period post each study injection (Days 0-27) ]

    Unsolicited local and/or systemic Adverse Events include any AE not include in the description of solicited AE, as described in Outcome 1 and 2.

    A visit will be schedule to occur 28 days after each study injection. Study staff will review the Participant Diary and interim history with the participant and inquire about new medical events, which will be recorded in the appropriate Clinical Research Forms.


  2. Number of participants with Serious Adverse Events over the 222-day period post second study injection. [ Time Frame: 222-day period post the second study injection (Days 0-221) ]

    Serious Adverse Event (SAE) is defined as an adverse event that meets one of the following conditions:

    • Death.
    • Life-threatening.
    • Requires inpatient hospitalization or prolongation of existing hospitalization.
    • Results in congenital anomaly/birth defect.
    • Results in a persistent or significant disability or incapacity.
    • Important medical events that might not result in death, be life-threatening, or require hospitalization might be considered SAEs when, based upon appropriate medical judgment, the event might jeopardize the well-being of the participant and require medical or surgical intervention to prevent one of the outcomes listed above.

    Participants will be contacted by phone on Day 222 after administration of second dose of study product for (a) closure of any ongoing AEs and concomitant medications; and (b) collection of any SAEs and new concomitant medications, if associated with the SAE reported.


  3. Number of participants that presented seroconversion at day 28, 45 and 56 post first study injection [ Time Frame: 56-day period post the first study injection ]

    Seroconvertion is defined as: prevaccination Hemagglutination-inhibition test (HI) antibody titer ≤1:10 and postvaccination HI antibody titer ≥1:40, or prevaccination HI antibody titer ≥1:10 and a postvaccination increase by a factor of four or more).

    Participants will be invited to return on days 28, 45 and 56 post first study injection, when blood samples will be taken for HI testing.


  4. Number of participants that presented seroprotection at day 28, 45 and 56 post first study injection [ Time Frame: 56-day period post the first study injection ]

    Seroprotection is defined as postvaccination Hemagglutination-inhibition test (HI) antibody titer ≥ 1:40.

    Participants will be invited to return on days 28, 45 and 56 post first study injection, when blood samples will be taken for HI testing.


  5. Geometric mean of Hemagglutination-inhibition titre at day 28, 45 and 56 post first study injection [ Time Frame: 56-day period post the first study injection ]

    Geometric mean of Hemagglutination-inhibition test titre will be calculated for the different groups of participants at day 28, 45 and 56 post first study injection.

    Participants will be invited to return on days 28, 45 and 56 post first study injection, when blood samples will be taken for HI testing.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 59 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy male or female (non-pregnant) adults 18 through 59 years of age at the enrollment visit.
  • To be available to participate in the study throughout its duration (approximately seven months).
  • Healthy, as established by the medical history, physical examination, and screening laboratory evaluations.
  • Capable and willing to complete Participant Diaries and willing to return for all follow-up visits.
  • To demonstrate intention to participate in the study, as documented by signature in the study´s informed consent form.
  • For females of child-bearing potential, willing to utilize reliable birth control measures from Day 0 through at least 60 days following the last study vaccination.

Exclusion Criteria:

  • Participation in another clinical trial involving any experimental therapy within the previous three months or planned enrollment in such a trial during the period of this study.
  • Evidence of active neurological, cardiac, pulmonary, hepatic or renal disease as clinical history and/or physical examination (except hypertension under control).
  • Compromised immune system diseases including: HIV, Hepattis B and C, diabetes mellitus, cancer (except basal cell carcinoma) and autoimmune diseases.
  • Behavioral, cognitive or psychiatric disease that in the opinion of the principal investigator or his representative physician, affects the participant ability to understand and cooperate with all study protocol requirements.
  • Abusive usage of alcohol or drugs in the past 12 months that has caused medical, professional or family problems, indicated by clinical history.
  • Known systemic hypersensitivity to eggs or to any component of the vaccine.
  • History of severe adverse reaction after previous administration of an Influenza vaccine within 6 weeks following vaccination.
  • History of Guillain-Barre Syndrome or other demyelinating disease.
  • Have a history of severe reactions following previous immunization with licensed or unlicensed influenza virus vaccines.
  • Diagnosis of asthma with a history of hospitalization related to this condition in the last six months due to illness.
  • Suspected or confirmed fever in the 3 days prior to vaccination or axillary temperature greater than 37.8 ° C on the day of vaccination.
  • Use of corticosteroids (except topical or nasal) or other immunosuppressive drugs within 42 days before study initiation/baseline. It will be considered immunosuppressive dose of corticosteroids the equivalent to a dose ≥10 mg of prednisone per day for over 14 days.
  • Impaired coagulation due to chronic disease or due to use anticoagulant medication (warfarin or heparin) in the 7 days preceding vaccination.
  • Have received live virus vaccine within 28 days or killed virus vaccine in the last 14 days prior to vaccination, or have a scheduled immunization from the first study vaccination until 21 days after the second vaccination.
  • Have received any influenza A/H7 vaccine.
  • History of asplenia.
  • Have received blood products in the past 6 months, including transfusions or immunoglobulin, or scheduled administration of blood products or immunoglobulin for the first 21 days after vaccination.
  • Any other condition that might put at risk the safety/rights of a potential participant or his/her compliance with this protocol in investigator's opinion or his representative physician.
  • Laboratory values at screening equal to or greater than Grade 2 will be considered to be exclusionary. Vital signs may be performed up to three times to allow for transient conditions to resolve. Screening laboratory values that are out of range, but are considered to be due to an acute illness or process may be repeated once. Grade 1 laboratory values will be reviewed by a licensed study clinician and the clinician will determine whether the laboratory abnormality is clinically significant and should be considered exclusionary. If determined to be clinically insignificant, the study team is not required to follow the laboratory until resolution or the value is determined to be clinically stable.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03330899


Locations
Layout table for location information
Brazil
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo
Ribeirao Preto, SP, Brazil, 14015-069
Centro de Pesquisas Clínicas do Instituto Central do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
Sao Paulo, SP, Brazil, 05403 000
Centro de Pesquisa Clínica do Instituto da Criança do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo - ICr/HCFMUSP
Sao Paulo, SP, Brazil, 05415009
Sponsors and Collaborators
Butantan Institute
Investigators
Layout table for investigator information
Principal Investigator: Esper Kallas, PhD University of São Paulo
Layout table for additonal information
Responsible Party: Butantan Institute
ClinicalTrials.gov Identifier: NCT03330899    
Other Study ID Numbers: FLP-01-IB
First Posted: November 6, 2017    Key Record Dates
Last Update Posted: September 30, 2020
Last Verified: September 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Influenza, Human
Influenza in Birds
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases